Tags

Type your tag names separated by a space and hit enter

Recent developments in drug-induced movement disorders: a mixed picture.
Lancet Neurol 2019; 18(9):880-890LN

Abstract

A large and ever-growing number of medications can induce various movement disorders. Drug-induced movement disorders are disabling but are often under-recognised and inappropriately managed. In particular, second generation antipsychotics, like first generation agents, are associated with potentially debilitating side-effects, most notably tardive syndromes and parkinsonism, as well as potentially fatal acute syndromes. Appropriate, evidence-based management is essential as these drugs are being prescribed to a growing population vulnerable to these side-effects, including children and elderly people. Prevention of the development of drug-induced movement disorders is an important consideration when prescribing medications that can induce movement disorders. Recent developments in diagnosis, such as the use of dopamine transporter imaging for drug-induced parkinsonism, and treatment, with the approval of valbenazine and deutetrabenazine, the first drugs indicated for tardive syndromes, have improved outcomes for many patients with drug-induced movement disorders. Future research should focus on development of safer antipsychotics and specific therapies for the different tardive syndromes and the treatment of drug-induced parkinsonism.

Authors+Show Affiliations

Jean and Paul Amos Parkinson's Disease and Movement Disorders Program, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: sfactor@emory.edu.Department of Neurology, Faculty of Medicine, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.Corporal Michael J Crescenz VA Medical Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA.Edmond J Safra Program in Parkinson's Research, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada.Department of Neuroscience, Biomedicine, and Movement, University of Verona, Verona, Italy.Department of Neurological Sciences, Rush Medical College, Chicago, IL, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31279747

Citation

Factor, Stewart A., et al. "Recent Developments in Drug-induced Movement Disorders: a Mixed Picture." The Lancet. Neurology, vol. 18, no. 9, 2019, pp. 880-890.
Factor SA, Burkhard PR, Caroff S, et al. Recent developments in drug-induced movement disorders: a mixed picture. Lancet Neurol. 2019;18(9):880-890.
Factor, S. A., Burkhard, P. R., Caroff, S., Friedman, J. H., Marras, C., Tinazzi, M., & Comella, C. L. (2019). Recent developments in drug-induced movement disorders: a mixed picture. The Lancet. Neurology, 18(9), pp. 880-890. doi:10.1016/S1474-4422(19)30152-8.
Factor SA, et al. Recent Developments in Drug-induced Movement Disorders: a Mixed Picture. Lancet Neurol. 2019;18(9):880-890. PubMed PMID: 31279747.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recent developments in drug-induced movement disorders: a mixed picture. AU - Factor,Stewart A, AU - Burkhard,Pierre R, AU - Caroff,Stanley, AU - Friedman,Joseph H, AU - Marras,Connie, AU - Tinazzi,Michele, AU - Comella,Cynthia L, Y1 - 2019/07/03/ PY - 2018/11/11/received PY - 2019/03/17/revised PY - 2019/03/19/accepted PY - 2019/7/8/pubmed PY - 2019/7/8/medline PY - 2019/7/8/entrez SP - 880 EP - 890 JF - The Lancet. Neurology JO - Lancet Neurol VL - 18 IS - 9 N2 - A large and ever-growing number of medications can induce various movement disorders. Drug-induced movement disorders are disabling but are often under-recognised and inappropriately managed. In particular, second generation antipsychotics, like first generation agents, are associated with potentially debilitating side-effects, most notably tardive syndromes and parkinsonism, as well as potentially fatal acute syndromes. Appropriate, evidence-based management is essential as these drugs are being prescribed to a growing population vulnerable to these side-effects, including children and elderly people. Prevention of the development of drug-induced movement disorders is an important consideration when prescribing medications that can induce movement disorders. Recent developments in diagnosis, such as the use of dopamine transporter imaging for drug-induced parkinsonism, and treatment, with the approval of valbenazine and deutetrabenazine, the first drugs indicated for tardive syndromes, have improved outcomes for many patients with drug-induced movement disorders. Future research should focus on development of safer antipsychotics and specific therapies for the different tardive syndromes and the treatment of drug-induced parkinsonism. SN - 1474-4465 UR - https://www.unboundmedicine.com/medline/citation/31279747/Recent_developments_in_drug-induced_movement_disorders:_a_mixed_picture L2 - https://linkinghub.elsevier.com/retrieve/pii/S1474-4422(19)30152-8 DB - PRIME DP - Unbound Medicine ER -